New EFPIA leadership seeks to alter incoming pharma reforms

26 June 2023
european_union_commission_brussels_large

The newly-elected presidency team of Europe’s leading trade body has met to discuss the industry’s growing concern over the impact of  proposed changes to pharmaceutical legislation in the region.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has previously  suggested the changes amount to a “sabotage” of the industry.

Lawmakers in Europe want to introduce a shorter period of exclusivity for novel medicines and other changes such as a voucher system for new antibiotics and a simpler regulatory submission process.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical